A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (NCT06521567)
Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this interventional study is to determine the strength of cobolimab and dostarlimab that is most tolerated in children and young adults who have advanced solid tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab combination in children and young adults, (b) to see how to manage the side effects that may occur, and (c) the effect of this treatment in participants
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Los Angeles, California
Age range: 0 Years to 21 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — Hackensack, New Jersey
- GSK Investigational Site — Cincinnati, Ohio
- GSK Investigational Site — Providence, Rhode Island
- GSK Investigational Site — Madison, Wisconsin
- GSK Investigational Site — Brno,
- GSK Investigational Site — Phaha 5,
- GSK Investigational Site — Copenhagen,
- GSK Investigational Site — Bordeaux,
- GSK Investigational Site — Lyon,
- GSK Investigational Site — Paris,
- GSK Investigational Site — Strasbourg,
- GSK Investigational Site — Villejuif,
- GSK Investigational Site — Bologna,
- GSK Investigational Site — Naples,
- GSK Investigational Site — Barcelona,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Madrid,
- GSK Investigational Site — Valencia,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma
- Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy — San Francisco, California
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Tucson, Arizona
- Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. — CABA, Buenos Aires
- Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients — Santa Monica, California
- NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma — Boston, Massachusetts
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Orlando, Florida
Explore by condition: All Melanoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.